Abivax (ABVX) said Monday it closed its previously announced public offering of 7.36 million American depositary shares, including the full exercise of the underwriters' option to purchase additional ADSs.

The offering generated aggregate gross proceeds of approximately $920 million, with estimated net proceeds of approximately $874.1 million, according to a statement.

Abivax said the net proceeds, together with its current cash and cash equivalents, will fund operations into Q4 of 2029.